Objective To characterize the management of acute pediatric supraventricular tachycardia (SVT), placing special emphasis on infants, patients refractory to adenosine (refractory SVT), and patients with hypotension, poor perfusion, or altered mental status (unstable SVT).
S upraventricular tachycardia (SVT) is the most common pediatric tachyarrhythmia in children. The use of vagal maneuvers and adenosine for the acute management of SVT is the current standard of care. 1, 2 Adenosine is an endogenous nucleoside ubiquitous in humans. Its mechanism of action for decreasing the heart rate in SVT is through the binding of adenosine receptors in the sinoatrial, atrioventricular nodes, and atrial myocytes. 3 Since its first use in children in 1987, 4 adenosine has been established as a safe and effective medication for acute SVT, with quick onset and a short half-life of less than 10 seconds.
Current guidelines developed by the International Liaison Committee on Resuscitation and the American Heart Association (AHA) define adenosine dosing and administration for the first 2 doses as 0.1 and 0.2 mg/kg, respectively, or 6 and 12 mg, respectively, for older children. In cases of SVT with cardiovascular instability (hypotension, impaired perfusion) without altered mental status, it is recommended that adenosine be used only if it does not delay cardioversion, whereas immediate cardioversion is recommended for patients with SVT and altered mental status. 5 The International Liaison Committee on Resuscitation and the AHA recently identified important knowledge gaps and areas needing future investigation for the treatment of pediatric SVT related to the efficacy of various vagal maneuvers, choice of antiarrhythmic medication in patients refractory to the first 2 doses of adenosine (refractory SVT), and use of electrical therapy in patients with cardiovascular instability and altered mental status. In addition to these identified areas of uncertainty, recent reports suggest that infants might be less responsive to adenosine. [6] [7] [8] We sought to perform an analysis of cases of pediatric SVT in patients without a history of congenital heart disease treated at our tertiary care facility, with a particular focus on infants, patients refractory to first 2 doses of adenosine, and patients presenting with hypotension, poor perfusion, or altered mental status (unstable SVT). Our primary hypothesis was that infants have lower response rates to
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International Classification of Diseases, Ninth Revision ICU Intensive care unit SVT Supraventricular tachycardia adenosine and a greater prevalence of refractory SVT compared with children 1 year and older. Our secondary hypothesis was that patients with unstable SVT are treated rarely with synchronized cardioversion.
Methods
We included patients aged 0-18 years evaluated at our facility for acute SVT from January 1, 2003, through December 31, 2012. We excluded patients with a history of structural heart disease or previous cardiac surgery. To capture the preponderance of patients with acute SVT episodes in Western Pennsylvania, we reviewed the medical records of all pediatric patients who were (1) treated for SVT in the emergency department (ED), inpatient ward, or pediatric cardiac intensive care unit (ICU); (2) referred to our facility for further care after being treated at a referring facility; or (3) treated by paramedics and transported to our hospital. Our pediatric tertiary facility is the only children's hospital in Western Pennsylvania and therefore has a large catchment area. The study was approved by the institutional review board of the University of Pittsburgh. Acute episodes of SVT were identified by 3 mechanisms. We first identified episodes of acute SVT by searching the electronic medical record for International Classification of Diseases, Ninth Revision (ICD-9) codes 427.0 (SVT), 427.89 (other arrhythmia), 427.1 (ventricular tachycardia), 427.41 (ventricular fibrillation), and 427.9 (cardiac arrhythmia). This query result was cross-referenced against ICD-9 code 99.62 for cardioversion to identify any potential patients who were treated by synchronized cardioversion and did not receive the ICD-9 code for SVT. In addition, a separately maintained cardiology database containing all patients with a diagnosis of SVT followed by our cardiology division was reviewed, and the medical records of all patients contained in this database and who were not captured by our ICD-9 code search were included. Patients with atrial tachycardia, atrial flutter, atrial fibrillation, and ventricular tachycardia were excluded from the analysis. For each patient identified via the use of these methods, we reviewed the medical record and identified each episode of acute SVT.
SVT was defined as tachycardia originating above the ventricles but not including atrial fibrillation or flutter. An episode of SVT was defined as documentation in the attending physician's clinical note and confirmation of the diagnosis on subsequent cardiology notes, specific appearance of electrocardiogram on a 12-lead electrocardiogram or telemetry monitor strip (tachycardia and absence of beat-to-beat variability), and treatment with vagal maneuvers, adenosine, other antiarrhythmics, or documentation of spontaneous resolution of SVT in the medical record. First presentation of SVT was defined as the first time a patient presented to our facility for treatment of SVT during the study period. Spontaneous conversion was defined as conversion to sinus rhythm in the absence of vagal maneuvers or administration of medications. Refractory SVT was defined as an episode of SVT that did not convert to sinus rhythm despite the administration of 2 doses of adenosine at or above the AHA-recommended doses. Unstable SVT was defined as the occurrence of hypotension, altered mental status, or documentation on physical examination of poor perfusion during an episode of SVT. 5 Hypotension was recorded as such if there was documentation of hypotension in the physician's medical record and the systolic blood pressure was lower than 2 × age (years) + 70 mm Hg. The general management of low blood pressure measurement in our ED consists of manual blood pressure measurement if the automated blood pressure measurement is below the normal range. Response to a specific maneuver was defined as conversion to sinus rhythm and maintenance of the sinus rhythm for at least 5 minutes after the respective intervention, which is consistent with definitions of conversion in previous publications of adenosine efficacy. 9 Some episodes responded to a specific therapy; however, the SVT recurred during the hospital stay, requiring further therapy. The subsequent SVT episodes occurring during the hospital stay were not included in the analysis.
Once identified as an acute SVT episode, each encounter was reviewed, including ED records, records of the hospital course, prehospital and transport records, and referring facilities' records when applicable. Where available, the results of echocardiogram were recorded.
Statistical Analyses
Research data were collected with the Research Electronic Data Capture (REDCap) software. Data were analyzed with the statistical package SigmaStat (Systat Software, Inc, San Jose, California). Data are presented as mean ± SD. The outcome variables of interest were spontaneous cessation of SVT, response to vagal maneuvers, response to first dose of adenosine, response to second dose of adenosine, and presence of refractory SVT, all of which were classified as one for "yes" and zero for "no." Multiple linear logistic regression models were fit to test whether age was a risk factor for different SVT therapies. Model fit statistics such as deviance and Pearson c 2 statistic were examined, as well as Pearson residuals. No assumption violations were detected by examining the model fit and residual plots. The c 2 test was used to compare the outcome for different treatments of acute SVT in the age groups: younger than 1 year vs 1 year and older, and weight groups: <10 kg vs ≥10 kg.
Results
During the 10-year study period, we identified 179 episodes of acute SVT in 134 patients. Of these patients, 110 had a single episode, and 24 had multiple episodes. Demographics for our patient population are presented in Table I (available at www.jpeds.com). Mean age was 7.4 ± 5.8 years, racial breakdown was 85% white and 15% black, and breakdown by sex was 62% male and 38% female patients. A history of SVT was recorded in 25% of patients, and 9.7% were treated with daily antiarrhythmics. The management of SVT in our population is presented in Figure 1 (available at www.jpeds.com).
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Spontaneous cessation of SVT occurred in 24 (13%) episodes of SVT. Age was not associated with spontaneous cessation (OR 0.9, 95% CI 0.75-1.07; Table II ). Vagal maneuvers were recorded as attempted in 109 (61%) episodes and were successful in 27 (25%) episodes. Application of ice to the face and blowing in a blocked straw were the most successful vagal maneuvers (Figure 1) . Age was not associated with the success of vagal maneuver (OR 0.99, 95% CI 0.84-1.17; Table II) .
A first dose of adenosine was administered in 128 episodes. Conversion to sinus rhythm occurred in 72 (56%) episodes. The mean first dose of adenosine administered was 0.1 ± 0.03 mg/kg, with a range of 0.05-0.25 mg/kg. Six patients aged 4-10 years received a substandard first dose of adenosine (0.05-0.09 mg/kg), 3 of whom converted to sinus rhythm. The conversion to sinus rhythm after the first dose of adenosine increased proportionally with age (OR 1.13, 95% CI 1.05-1.2; Table II) .
A second dose of adenosine was administered in 54 episodes, with conversion to sinus rhythm occurring in 27 (50%) episodes. The mean second dose of adenosine administered was 0.2 ± 0.07 mg/kg (range 0.1-0.48 mg/kg). Three patients aged 4-8 years received a substandard second dose of adenosine (0.1-0.16 mg/kg), and all converted to sinus rhythm after this dose. Age was not associated with conversion to sinus rhythm after the second dose of adenosine (OR 1.03, 95% CI 0.94-1.13; Table II ). Analysis of the 134 patients with a first presentation of SVT was not different than data analyzed for all episodes of SVT (data not shown).
Characteristics and Treatment of Refractory SVT
Refractory SVT occurred in 27 episodes, representing 15% of all acute SVT episodes. All 27 episodes with refractory SVT received adenosine at or above the AHA recommended doses. In multiple linear logistic regression among all episodes of SVT, younger age was associated with refractory SVT (OR 0.9, 95% CI 0.85-0.99; Table II) . Analysis of patients with first presentation of SVT was similar to data analyzed for all episodes (data not shown).
Twenty-three of 27 (85%) episodes of refractory SVT were treated with additional (≥3) doses of adenosine. Treatment of refractory SVT is detailed in Figure 2 (available at www.jpeds.com). There were 12 episodes of persistent SVT after 3 doses of adenosine, and these were treated further with one or more antiarrhythmic agents. Of episodes with refractory SVT, 2 patients were treated with synchronized cardioversion. Seven patients with refractory SVT left the ED in SVT and were admitted to the ICU for further management (Figure 2) . Various antiarrhytmic medications were used for patients with refractory SVT. Most frequently used antiarrhythmics were digoxin and propranolol in infants and amiodarone and procainamide in older children (Figure 2 and Tables III and IV). All patients with refractory SVT had good outcome and were discharged from the hospital. Unstable SVT was present in 10 patients with refractory SVT.
Presentation and Management of Infants (<1 Year
Old) Presenting with SVT SVT occurred in infants in 33 (18%) episodes during our study period. Infants presented with the following chief complaints: tachycardia detected at well child visit (n = 7, 21%), poor oral intake (n = 7, 21%), labored breathing (n = 6, 18%), fussiness (n = 6, 18%), tachycardia detected by home monitor (n = 3, 9%), tachycardia detected by a parent in infants with a history of SVT (n = 2), and pallor (n = 1). One infant (1 day old) with history of fetal tachycardia developed tachycardia in the newborn nursery and was transferred to our hospital (Table III) .
Sixteen (48%) SVT episodes in infants converted to sinus rhythm either spontaneously or after vagal maneuvers. The success of vagal maneuvers was greater in infants compared with children 1 year and older (c 2 = 6.8 [1 df], P = .009). Conversely, conversion to sinus rhythm after a first dose of adenosine was lower in infants compared with children 1 year and older (c 2 = 17.9 [1 df], P < .001) and lower for episodes with weight <10 kg compared with ≥10 kg (c 2 = 18.4 [1 df], P < .001). Of 17 episodes of SVT in infants in whom a first dose of adenosine was administered, only one converted to sinus rhythm (0.05%), vs 16 of 111 responses to a first dose of adenosine in children older than 1 year of age (14%). All infants received adequate first dose of adenosine (≥0.1 mg/kg).
Of 16 episodes of SVT in infants in whom a second dose of adenosine was administered, 6 converted. There was no difference in the response to the second dose of adenosine for b is the parameter estimate from the logistic model, SE(b) is the SE of b, Wald test is a test statistic testing the hypothesis of b = 0, and the 95% CI presents the lower and the upper value of the estimated parameter, ie, if the experiment were to be performed 100 times on the same data under the same conditions, then 95% of the time the estimate will be in that interval.
episodes in patients younger than 1 year vs those 1 year and older (c Refractory SVT occurred in 10 of 33 (27%) infants vs 17 of 146 (12%) in age 1 year and older. The rate of refractory SVT was greater in infants compared with patients older than 1 year (c 2 = 5.9 [1 df], P = .01), and in patients with weight <10 kg vs ≥10 kg (c 2 = 5.2 [1 df], P = .02). Analysis of first presentations of SVT in infants was similar to data analyzed for all episodes (data not shown).
Echocardiography revealed decreased biventricular function in 4 infants with refractory SVT (7, 12, 28 days, and 9 months old). Decreased ventricular function was not reported for older children, although only few echocardiographs were recorded for our patients. Two patients, 7 days old and 12 days old, had severe heart failure requiring mechanical support and milrinone for heart failure, respectively (Tables III and IV). All infants with refractory SVT had good outcome and were discharged from the hospital.
Management of Patients with Unstable SVT
Unstable SVT occurred in 13 patients in our series (Table IV) . Four patients had hypotension alone. Seven patients had altered mental status alone. Two patients had both altered mental status and hypotension. All patients with unstable SVT initially were treated with vagal maneuvers, all unsuccessful, and adenosine. Five of 13 (38%) patients converted to sinus rhythm after 1-3 doses of adenosine. The remaining 8 patients were given antiarrhythmic medications, and 6 patients responded. The 2 patients with unstable SVT who did not respond to antiarrhythmic medications were treated with synchronized cardioversion; one cardioversion was performed in the ED and one was performed after the patient was transported to the ICU. All patients with unstable SVT had good outcome and were discharged from the hospital.
Synchronized Cardioversion
In our study, we found that electrical cardioversion was performed only in episodes of refractory SVT. During the 10-year study period, synchronized cardioversion was performed in our institution 3 times for SVT in patients without congenital heart disease. Two electrical cardioversions were performed after the patient was transferred to the ICU, and one occurred in the ED. Sedation was given before cardioversion in 2 of the 3 patients, 10 and 13 years of age, and was not administered to a 22-day-old infant. The doses of synchronized cardioversion were 0.75 J/kg, 0.5 J/kg, and 1.6 J/kg, respectively. All 3 patients converted to sinus rhythm with the first electrical dose administered. They were hospitalized in the cardiac ICU and were admitted for 3, 11, and 10 days, respectively. All 3 patients had subsequent episodes of SVT during 
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Discussion
Overall, adenosine was effective for the successful termination of SVT: 79% of episodes converted to sinus rhythm after 1 or 2 doses of adenosine. This finding is similar to previously published studies, where the success rates of adenosine were 60%-80%. [10] [11] [12] Importantly, we found a very low conversion rate of infants after a first dose of adenosine. Only 1 of 17 episodes in infants responded to adenosine, and the patient who responded was nearly 1 year of age.
Refractory SVT also occurred with greater frequency in infants. A low response rate in infants has been described previously, with proportion of infants responding varying from 9% to 35%. 7, 8, [13] [14] [15] In one series of infants ages 0-72 days of age, conversion rates were reported as 9% for adenosine doses of 0.05 mg/kg and 35% for doses of 0.15 mg/kg. Similarly, in our study, one infant converted when adenosine 0.1 mg/kg was administered and one-third of infants converted when a dose of 0.2 mg/kg was administered.
The reason for a low response rate to adenosine in infants is not clear. We postulate the following possible mechanisms: (1) inadequate delivery of adenosine to infants, either secondary to the slow rate of infusion accomplished by using a small intravenous catheter, intravenous access site location far from the conduction system, or by a proportion of adenosine not being cleared by the saline flush from the 3-way stopcock; (2) relative resistance of infants' atrioventricular node to adenosine; or (3) infants' presentation to evaluation later in the course of the illness, which might be associated with low response to treatment secondary to lower cardiac output. At this time, a recommendation to increase the dose of adenosine administered to infants appears feasible and safe. A dose of 0.2 mg/kg was well tolerated by all infants in our series. Dixon et al 7 and Qureshi et al 6 also reported greater conversion rates when 0.2 mg/kg was administered. Some authors suggested starting with 0.2 mg/kg in infants, and our data support this approach. 8, 16 Several infants were discovered to be in SVT at a well child check or at unrelated healthcare visit. Infants presented with the common complaints of poor feeding, fussiness, or labored breathing, and a small number of infants, on presentation to the ED, were found to be very ill, suggesting they had been in Table IV . Unstable SVT SVT for a longer time. Although SVT is often a well-tolerated phenomenon, in a setting of prolonged tachycardia, it may be associated with significant morbidity. Four infants in our study had depressed myocardial function on echocardiogram. Evaluation of infants with fussiness or other nonspecific symptoms should include consideration of a tachyarrhythmia.
Our study identified 13 patients who met the definition of unstable SVT, 3 of whom were infants. In all patients with unstable SVT, vagal maneuvers were attempted and did not result in conversion to sinus rhythm. Ultimately, 11 of the 13 unstable patients were managed with medications alone (without electrical cardioversion), contrary to AHA guidelines for synchronized cardioversion in these patients. Although there was no apparent harm to these children other than delayed cardioversion to sinus rhythm, our study highlights a possible reluctance to electrically cardiovert pediatric patients, even among providers at a tertiary children's hospital.
In our 10-year study, synchronized cardioversion was performed for treatment of SVT in 3 patients, and only once in the ED. After synchronized cardioversion the patient required cardiorespiratory support and ICU care. In addition, electrical cardioversion was performed only twice in the ICU for SVT. One patient was refractory to adenosine but stable, and one patient was unstable. From this limited number of synchronized cardioversions, we could not determine whether cardioversion in infants with low ejection fraction could be associated with increased risk of complications. Careful consideration for readiness for airway and cardiovascular support should be part of the preparation for electrical cardioversion for such patients.
Our study has some limitations. Because of the retrospective nature of the study, some variables of particular interest, such as the site of intravenous catheter or duration of SVT before conversion, were not available. Inability to rapidly push the adenosine due to a small intravenous line may have resulted in failure of termination of SVT. In addition, some patients may have had vagal maneuvers performed before arrival, but not documented, especially if unsuccessful. We based our definition of conversion to sinus rhythm as sustained sinus rhythm for 5 minutes after a certain intervention, consistent with previously published data 9 and relevant to clinical practice. Given that the half-life of adenosine is seconds, abrupt termination of tachycardia with adenosine and rapid reinitiation of tachycardia following brief termination might be considered by some evidence of successful response. In this study, we presented the data per episode of SVT, consistent with other studies of SVT. 6, 7, 10 To assure that our data do not overrepresent patients with difficult-to-manage SVT, we also analyzed data separately on first presentation of SVT and obtained similar results. Even though this study originates from a center with a large catchment area, we do not know how many patients were treated at outside facilities and not referred to our ED. Consequently, referral bias might exist in our study, especially for children with spontaneous termination, or successfully treated at other facilities or in prehospital who might not have been referred. In addition, because this study originated from a single site, there may be institution bias with regard to SVT diagnosis and management.
In stable patients with episodes that are refractory to adenosine, medical management with serial adenosine or other antiarrhythmics was successful in the majority of episodes. In the treatment of unstable SVT, there may be a role for medical management with various antiarrhythmics before cardioversion. ■ 
